C2 Therapeutics, a privately-held company founded to improve treatment of precursors to esophageal cancer (Barrett’s esophagus or BE), today announced that two studies reinforcing the clinical efficacy and safety of its Coldplay CryoBalloon® Focal Ablation System were presented at United European Gastroenterology Week, held in Barcelona from October 24-28.
https://www.businesswire.com/news/home/20151110005676/en/C2-Therapeutics-Announces-Data-Confirming-Efficacy-Safety
C2 Therapeutics Announces New Data Confirming Efficacy and Safety of Coldplay CryoBalloon® Focal Ablation System to Treat Esophageal Disease